Meldonium: drug which brought disrepute to sport

Bikash Ranjan Meher¹*, Smita Das², Rashmi Ranjan Mohanty³

¹Department of Pharmacology, All India Institute of Medical Science, Bhubaneswar, Odisha, India
²Department of Pharmacology, IMS and SUM Hospital and Medical College, Bhubaneswar, Odisha, India
³Department of General Medicine, All India Institute of Medical Science, Bhubaneswar, Odisha, India

Received: 08 June 2017
Accepted: 29 June 2017

*Correspondence to:
Dr. Bikash Ranjan Meher,
Email: bikash1meher@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

World of sports have been rocked by doping scandals every now and then and World Anti-Doping Agency (WADA) has banned several offending drugs at different times to counter this menace. Meldonium is the recent addition to the long list of drugs banned by WADA to prevent its misuse among the athletes. Meldonium is a carnitine synthesis inhibitor and has been approved by some European countries for the management of cardiac diseases like angina pectoris and congestive cardiac failure. Apart from these, it has numerous other indications like bronchial asthma, bronchitis and retinopathies. It had also been used by athletes across the world because of its presumptive role in increasing the performance.

Keywords: Doping, L-Carnitine, Meldonium

INTRODUCTION

Sport has always been marred by doping scandals and controversies. But it reached mammoth proportion, when part of Russian contingent was banned from Rio Olympics. In the beginning of this year tennis fans across the world were stunned by the shocking revelation of doping scandal involving a numero uno Russian tennis player, it was found that she was taking Mildronate for quite a long time, subsequently she was handed over a temporary ban by world tennis federation. Because of this and some other similar events in other disciplines of sport involving it, meldonium grabbed the eye ball across the world and adorned prominent pages in various newspapers. In view of these, world anti-doping agency (WADA) added this drug in its prohibited list, effective from first January 2016, although it was an old drug.¹

So, what exactly is Mildronate? This question is lurking in the mind of people in general and sport enthusiasts in particular across the world.
Mildronate is the brand name of meldonium. It was first manufactured by Baltic (Latvian) pharmaceutical company Grindeks and introduced as a growth promoting agent in animals. It was found to increase sperm motility, serum testosterone concentration and sexual performance in boar. Later different clinical studies established it as an agent having anti-ischemic and cardio protective effect. A large number of studies have been carried out to explore its pharmacological effects and therapeutic benefits. Most of its therapeutic effects are linked to its role in carnitine metabolism. This drug is not yet approved for use in USA or Western European nations, but available as both OTC (over the counter) and prescription drug in Eastern Europe.

**STRUCTURE OF MELDONIUM**

Chemically, meldonium is 3-(2, 2, 2-trimethylhydrazinium) propionate dihydrate. Its chemical structure resembles that of L-Carnitine and γ butyro betaine (Figure 1 and Figure 2).

![Figure 1: Chemical structure of L-Carnitine.](image)

![Figure 2: Chemical structure of meldonium.](image)

**PHARMACOKINETICS OF MELDONIUM**

Meldonium is a low molecular weight, water soluble compound and non-plasma protein binding in nature. Pharmacokinetic property of meldonium was observed in the healthy volunteers for single as well as multiple dose administrations. After single dose oral administration peak plasma concentration of drug was achieved in 2 hrs. Its elimination half-life was found to be 18 hrs. after oral administration. It was observed that elimination half-life of meldonium increased after multiple consecutive intravenous administrations in compare to single intravenous dose (15.34±3.14 hours from 6.55±1.17 hrs). It could be, because meldonium exhibited nonlinear kinetics after multiple administrations leading to accumulation of drugs. Meldonium inhibits organic cation transporter-2 (OCT-2) which transports carnitine, the peculiar feature is that meldonium also transported by OCT-2 and because of which it gets accumulated in tissues and hence shows a long elimination time.

**Mechanism of action**

It decreases the L-carnitine level by inhibiting its synthesis and promoting its elimination. A quaternary amine, L-carnitine plays an important role in fatty acid oxidation by transporting fatty acid from cytosol to mitochondria, the site of beta oxidation. Meldonium competitively inhibits the gamma butyro betane dioxygenase (gamma butyro betaine hydroxylase or BBOX) a key enzyme which carried out the final step of L-carnitine synthesis (Figure 3).

![Figure 3: Meldonium inhibits the enzyme Gamma butyro betane dioxygenase, which converts gamma butyro betaine to carnitine.](image)
PHARMACOLOGICAL ACTION AND THERAPEUTIC USES

Although meldonium was used initially to increase sperm motility and to enhance sexual performance, it is primarily known for its cardio protective effect. Studies have shown that, in different models of cardiovascular diseases it exerts cardio protective effect by inhibiting the L-carnitine level.20,21 In a study in knockout mice it was found out that it significantly reduces the development of atherosclerotic lesion in aorta and aortic sinus.22 Similarly in a study of acute myocardial ischemia rat model, meldonium treatment for 10 days reduced the myocardial infarct size.21 It also prolongs the survival, prevents the cardiac remodeling and improves the energy states in rats with congestive heart failure following myocardial infarction.22 In guinea pig meldonium treatment attenuates hypoxic and reperfusion injury in the isolated heart.23

Meldonium also have a significant role in metabolic diseases. In an animal model of diabetes (streptozotocin induced), it was found out that 6 weeks administration of meldonium reduced blood glucose and glycated hemoglobin level, improve glucose tolerance and prevented the development of diabetic associated.24,25 In another experiment with rats; it was observed that meldonium prevents endothelial dysfunctional changes occur with diabetes mellitus.26

In a clinical study, its role in post infarction period of CHF and diabetes mellitus was well demonstrated, where it tends to normalize the diastolic heart functions and increased the ejection fraction when given along with basic therapy.27 Similarly in a clinical trial by Dzerve et al, it was seen that in patient of stable angina pectoris meldonium improves the exercise performance.28

Although meldonium is used is not approved by USFDA but still it is widely used in Eastern European countries for multiple indications. It has been approved by different East European nations for use in angina pectoris, cardiomyopathy, abstinence syndrome in chronic alcoholism, bronchial asthma, obstructive bronchitis, hypertensive and diabetic retinopathies, neurodegenerative disorders, as immunomodulators, and many more.29

MELDONIUM IN SPORTS

A data analysis of meldonium use by athletes in 2015 Baku European games revealed that 66 of 762 athletes found positive for this drug before or during the game.30 Similarly in an analysis done by Gorgens et al, in 2015 in 8320 random urine sample of athletes from different discipline of sports, 182 were found to be positive for meldonate.31

To curb the increase misuse of this drug WADA had recently listed it as prohibited substance. WADA had issued a strong statement that “There is no doubt as to the status of meldonium as a prohibited substance,” and warned athletes across the world about the implications of its use WADA has classed it as an S4 substance which comprises hormones and metabolic modulators according (5.3).1,32

According to WADA report, 172 samples were found to be positive for meldonium since it has been announced as a banned drug, and this spans different sports and countries.33 This clearly speaks volume about its rampant misuse. The reason for this wide spread misuse of meldonium by athletes could be due to its low side effect profiles and its perceptible help in enhancing performance, it is assumed to increase the performance by increasing oxygen delivery to the peripheral tissue.33

Despite such hue and cry about its misuse, experts are divided its regarding its direct role on exercise performance. So, more studies are required for a clear-cut picture to emerge.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. World Anti-Doping Agency. The 2016 Prohibited List. Available at: http://www.usada.org/wp-content/uploads/wada-2016-prohibited-list-en.pdf (cited 14.11.2016).
2. USADA. Substance Profile: Meldonium. Secondary Substance Profile: Meldonium; 2016. Available at: http://www.usada.org/meldonium
3. Brveris Z, Antane V, Misane I, Rimeicans J, Lusis I, Auzans A, et al. Effects of meldonium on sexual performance, sperm motility, testes morphology and blood biochemical markers in boars. Anim Reprod Sci. 2013 Jan 30;136(4):303-9.
4. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med. 2002;12:275-9.
5. Sjakste N, Kalvinsh I. Mildronate: an antiischemic drug with multiple indications. Pharmacologyonline. 2006;1:1-18.
6. Sahartova O, Shatz V, Kalvins I. HPLC analysis of mildronate and its analogues in plasma. J Pharm Biomed Anal. 1993;11:1045-7.
7. Simkhovich BZ, Shutenko ZV, Meirēna DV, Khagi KB, Mežapuķe RJ, Molodchina TN, et al. 3-[(2, 2, 2-Trimethylhydrazinium) propionate (thp)-a novel γ- butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochemical pharmacology. 1988 Jan 15;37(2):195-202.
8. Zhao Z, Chen J, Peng W, Wang X, Chen Z, Tang H, et al. Single-and multiple-dose pharmacokinetic, safety and tolerability study of mildronate injection in healthy Chinese subjects pharmacokinetic of mildronate injection. Drug research. 2016 May;66(05):251-6.
9. Peng Y, Yang J, Wang Z, Wang J, Liu Y, Luo Z, et al. Determination of mildronate by LC-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. Journal of Chromatography B. 2010 Feb 15;878(5):551-6.

10. Zhang J, Cai LJ, Yang J, Zhang QZ, Peng WX. Nonlinear pharmacokinetic properties of mildronate capsules: a randomized, open-label, single-and multiple-dose study in healthy volunteers. Fundamental & clinical pharmacology. 2013 Feb 1;27(1):120-8.

11. Liepinsh E, Dambrova M. The unusual pharmacokinetics of meldonium: Implications for doping. Pharmacol Res. 2016 Sep;111:100.

12. Bremer J. Carnitine: Metabolism and functions. Physiological reviews. 1983 Oct 1;63(4):1420-80.

13. Simkhovich BZ, Shutenko ZV, Meirēna DV, Khagi KB, Mezapuke RJ, Molodchina TN, et al. 3-(2, 2, 2-Trimethylhydrazinium) propionate (thp)-a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochemical pharmacology. 1988 Jan 15;37(2):195-202.

14. Leung IK, Krojer TJ, Kochan GT, Henry L, von Delft F, Claridge TD, et al. Structural and mechanistic studies on γ-butyrobetaine hydroxylase. Chemistry & biology. 2010 Dec 22;17(12):1316-24.

15. Kuwajima M, Harashima H, Hayashi M, Ise S, Sei M, Lu KM, et al. Pharmacokinetic analysis of the cardioprotective effect of 3-(2, 2, 2-trimethylhydrazinium) propionate (thp)-a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochemical pharmacology. 1999 Apr 1;289(1):93-102.

16. Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Steiger B, et al. Development and characterization of an animal model of carnitine deficiency. The FEBS Journal. 2001 Mar 15;268(6):1876-87.

17. Dambrova M, Makreeca-Kuka M, Vilškersts R, Makarova E, Kuka J, Liepinsh E. Pharmacological effects of meldonium: biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacological research. 2016 Nov 30;113:771-80.

18. Jaudzems K, Kuka J, Gutsaïts A, Zinovjevs K, Kalvinš I, Liepinš E, et al. Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. Journal of enzyme inhibition and medicinal chemistry. 2009 Dec 1;24(6):1269-75.

19. Oppedisano F, Fanello D, Calvani M, Indiveri C. Interaction of mildronate with the mitochondrial carnitine/acylcarnitine transport protein. Journal of Biochemical and Molecular Toxicology. 2008 Feb 1;22(1):8-14.

20. Liepinš E, Vilškersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinš I, et al. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. Journal of cardiovascular pharmacology. 2006 Dec 1;48(6):314-9.

21. Vilškersts R, Liepinš E, Mateuszuk L, Grinberga S, Kalvinš I, Chlopicki S, et al. Mildronate, a regulator of energy metabolism, reduces atherosclerosis in apoE/LDLR−/− mice. Pharmacology. 2009;83(5):287-93.

22. Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, et al. Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. European journal of pharmacology. 2000 May 3;395(3):217-24.

23. Dhar PK, Grupp IL, Schwartz A, Grupp G, Matlab MA. Reduction of Carnitine Content by Inhibition of Its Biosynthesis Results in Protection of Isolated Guinea Pig Hearts Against Hypoxic Damage. J Cardiovasc Pharmacol Ther. 1996;1:235-42.

24. Sokolovska J, Isajevs S, Sugoka O, Sharipova J, Lauberte L, Svirina D, et al. Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model. Cell biochemistry and function. 2011 Jan 29(1):55-63.

25. Sokolovska J, Rumaks J, Karajeva N, Grinvalde D, Shapirova J, Klūša V, et al. The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rat streptozotocin-induced diabetes mellitus model. Biomedetinskaia khimiia. 2011;57(5):490-500.

26. Liepinš E, Vilškersts R, Zvejniecė L, Svalbe V, Skapare E, Kuka J, et al. Protective effects of mildronate in an experimental model of type 2 diabetes in goto-kakizaki rats. British journal of pharmacology. 2009 Aug 1;157(8):1549-56.

27. Sesti C, Simkhovich BZ, Kalvinš I, Kloner RA. Mildronate, a novel fatty acid oxidation inhibitor and antiischemic agent, reduces myocardial infarct size without affecting hemodynamics. Journal of cardiovascular pharmacology. 2006 Mar 1;47(3):493-9.

28. Dzerve V, Matison D, Pozdnyakov Y, Oganov R. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. InSeminars in Cardiovascular Medicine. 2010;16(3):1-8.

29. Sjakste N, Kalvinš I. Mildronate: an antiischemic drug with multiple indications. Pharmacologyonline. 2006;1:1-8.

30. Stuart M, Schneider C, Steinbach K. Meldonium use by athletes at the Baku 2015 European Games. Br J Sports Med. 2016;50:694-8.

31. Görgens C, Guddat S, Dib J, Geyer H, Schänzer W, Thevis M. Mildronate (Meldonium) in professional sports monitoring doping control urinesamples using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry. Drug Test Anal. 2015;7:973-9.

32. World Anti-Doping Agency. WADA statement on meldonium notice issued to stakeholders. Available at: https://www.wada-ama.org/en/media/news/2016-04/wada-statement-on-meldonium-notice-issued-to-stakeholders?(cited 12.122016).
33. Hughes D. Meldonium and WADA prohibited lists. Aust Prescr. 2016;39:102.

Cite this article as: Meher BR, Das S, Mohanty RR. Meldonium: drug which brought disrepute to sport. Int J Basic Clin Pharmacol 2017;6:1841-5.